Clinical Appropriateness Guidelines

Genetic Testing for Heredity Cardiac Disease

EFFECTIVE OCTOBER 14, 2017
# Table of Contents

Scope .................................................................................................................................................................. 3

Appropriate Use Criteria .................................................................................................................................. 3
  Confirmation/Diagnostic Testing .................................................................................................................. 3
  Testing of Asymptomatic Individuals ....................................................................................................... 3
  Post-Mortem Testing .................................................................................................................................. 3
  Long QT .................................................................................................................................................... 4
  Dilated Cardiomyopathy .............................................................................................................................. 5
  Tests Not Clinically Appropriate ........................................................................................................... 5

CPT Codes ....................................................................................................................................................... 5

Background ....................................................................................................................................................... 5
  Long QT .................................................................................................................................................... 6
  Dilated Cardiomyopathy .............................................................................................................................. 6
  Hypertrophic Cardiomyopathy .................................................................................................................... 7
  Brugada Syndrome ...................................................................................................................................... 8
  Short QT Syndrome ................................................................................................................................... 8
  Atrial Fibrillation ....................................................................................................................................... 8
  Post-Mortem Testing .................................................................................................................................... 9

Professional Society Guidelines ................................................................................................................... 9

Selected References ....................................................................................................................................... 10

Revision History ............................................................................................................................................. 11
Scope

This document addresses genetic testing for inherited arrhythmias and cardiomyopathies. Aortopathies and other connective tissue disorders with cardiac manifestations are NOT included in this document; see Genetic Testing for Single-Gene and Multifactorial Conditions Clinical Appropriateness Guidelines.

Appropriate Use Criteria

Confirmation/Diagnostic Testing

Confirmatory or diagnostic genetic testing for hereditary arrhythmias and cardiomyopathies is medically necessary when all of the following criteria are met:

- The individual is at risk for and/or has signs and symptoms of a hereditary cardiac disease
- The requested testing is as targeted as possible to a specific subset of genes related to the suspected condition (e.g. hypertrophic cardiomyopathy OR arrhythmogenic right ventricular cardiomyopathy/dysplasia)
- There are no additional relevant disease-specific criteria listed below

Testing of Asymptomatic Individuals

Single-site genetic testing for a known familial deleterious or suspected deleterious mutation is medically necessary for the following indications:

- hypertrophic cardiomyopathy (HCM)
- catecholaminergic polymorphic ventricular tachycardia (CPVT)
- dilated cardiomyopathy (DCM)
- Brugada syndrome
- arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)
- left ventricular non-compaction cardiomyopathy (LVNC)
- restrictive cardiomyopathy (RCM)

Post-Mortem Testing

Post-mortem cardiac genetic testing of an individual with sudden unexplained death, whose first degree family member is a covered member, is reasonable in the following circumstances:

- When the autopsy reveals evidence for a specific underlying heritable cardiac condition (e.g. ARVC, HCM, DCM, RCM) AND all of the following criteria are met:
  a. The corresponding targeted testing is ordered (e.g. HCM panel testing in cases where autopsy revealed evidence for HCM)
  b. No other living relative has clinical evidence for the suspected condition (e.g. should a living relative have evidence for HCM, then testing for the living relative is recommended)
• In ‘autopsy negative’ cases when all of the following criteria are met:

  a. The deceased individual meets one of the following:

    i. Age 40 years or younger at death

    ii. Over 40 years at death and there is a documented family history of sudden death or cardiomyopathy

  b. Cause for death remains unknown after completion of autopsy and toxicology testing (if completed)

  c. The test requested is a single gene or targeted panel test for common genetic causes of sudden cardiac arrest/death and/or is as targeted as possible for the clinical indication

**Long QT**

Genetic testing for long QT syndrome (LQTS) is medically necessary when the individual meets general criteria for hereditary cardiac genetic testing (above) and one of the following indications:

• confirmatory (i.e., diagnostic) testing when there is confirmed prolonged QT interval on electrocardiogram (ECG) or Holter monitor (i.e., corrected QT [QTc] interval of >470 msec [males] or >480 msec [females]), and an acquired cause has been ruled out

• predictive testing, when there is evidence in a first-degree relative of either of the following:

  o a history of prolonged QT interval on ECG or Holter monitor (i.e., corrected QT [QTc] interval of >470 msec [males] or >480 msec [females]) and the affected individual is not available for testing

  o sudden death of suspected cardiac diagnosis or near sudden death at age 40 or younger with no evidence of ischemia and no genetic testing was performed

• predictive testing for a known familial mutation for LQTS
**Dilated Cardiomyopathy**

Targeted single gene (DES, LMNA, SCN5A) OR multi-gene DCM panel genetic testing is medically necessary when the general criteria for hereditary cardiac genetic testing (above) are met in addition to the following:

- individual has a clinical diagnosis of dilated cardiomyopathy (DCM)
- individual has significant cardiac conduction disease (first-, second- or third-degree block) and/or family history of premature cardiac death (<50 years) in a first- or second-degree relative
- individual is a candidate for an ICD

**Tests Not Clinically Appropriate**

- Broad “multi-condition” panel testing (e.g. pan-cardio panel, arrhythmia panel) is not medically necessary.
- Genetic testing for short QT syndrome and atrial fibrillation is experimental, investigational and unproven.

**CPT Codes**

The following codes are associated with the guidelines outlined in this document. This list is not all inclusive.

- **81413** Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia); genomic sequence analysis panel, must include sequencing of at least 10 genes, including ANK2, CASQ2, CAV3, KCNE1, KCNE2, KCNQ2, KCNJ2, KCNQ1, RYR2, and SCN5A.

- **81414** Cardiac ion channelopathies (eg, Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia); duplication/deletion gene analysis panel, must include analysis of at least 2 genes, including KCNH2 and KCNQ1.

- **81439** Inherited cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) genomic sequence analysis panel, must include sequencing of at least 5 genes, including DSG2, MYPBC3, MYH7, PKP2, and TTN.

**Background**

Most forms of arrhythmias and cardiomyopathies are multifactorial. There are, however, several forms of Mendelian hereditary cardiac disease that cause severe and early-onset symptoms. The hereditary arrhythmias and cardiomyopathies are primarily diagnosed clinically and symptoms can be variable within the same family. Although genetic test results may not guide medical management for those with a clinical diagnosis, identification of a mutation can allow for detection of asymptomatic family members who might benefit from life-saving treatment. Most hereditary cardiac conditions are associated with multiple genes. Targeted panel testing is reasonable in most cases.
Long QT

Long QT syndrome (LQTS) is characterized by prolongation of the QT interval on electrocardiogram (ECG). LQTS disorders are considered channelopathies, or diseases that affect cardiac ion channels. This condition predisposes the individual to cardiac events and arrhythmias including: torsades de pointes, ventricular tachycardia, syncopal episodes, ventricular fibrillation and cardiac arrest.

LQTS is diagnosed by considering the clinical features, the family history, and the ECG findings of the patient. LQTS may be diagnosed when the prolongation of the QTc interval is >470 msec (males) or >480 msec (females) (Crotti 2008). The clinical features may range from minor symptoms such as dizziness, to more severe symptoms such as seizure, syncope and sudden death. Congenital LQTS will usually manifest before the age of 40 years, generally in childhood and adolescence with the age of onset associated with the genotype. Long-term management of LQTS may include lifestyle modification, beta-adrenergic blockers, permanent pacemaker implantation, and implantable cardioverter defibrillators.

At least 15 genes have been found to be associated with LQTS; however, mutations in 3 genes represent the most common causes: KCNQ1 (30-35%), KCNH2 (25-30%), and SCN5A (5-10%). Not all patients meeting clinical criteria for LQTS have detectable mutations in one of the known associated genes. The recommended testing approach includes either single gene sequencing or a multi-gene sequencing panel, which may be more cost effective given the multiple associated genes. Genetic screening may provide unique assistance to a family member with normal QT interval (Schwartz 2006), as at-risk individuals can be identified prior to the onset of symptoms.

Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM) is characterized by enlargement of the left ventricle of the heart and systolic impairment, in the absence of abnormal loading conditions or coronary artery disease sufficient to cause global systolic dysfunction (Haas 2015). The symptoms of DCM are similar to heart failure including shortness of breath, chest pain/tightness, fainting episodes and cardiac arrhythmias. The most serious complication of DCM is sudden, irregular heart rhythms that can be life threatening. Some individuals with DCM will have no symptoms throughout their lifetime.

DCM is a heterogeneous condition caused by ischemia, systemic disease (e.g. mitochondrial or muscular dystrophy), toxins, or infection. Twenty to 50 percent of cases of idiopathic DCM are inherited. DCM can be inherited as an X-linked, autosomal recessive or autosomal dominant condition. Autosomal dominant is the most common form of inherited DCM. There are at least 38 different genes known to cause DCM and many more genes implicated as associated with the condition. Genetic testing is available for multiple DCM genes, typically in large multi-gene panels. Genetic testing identifies a mutation in 22-50% of cases.

The 2011 HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies recommends comprehensive (testing all clinically available DCM genes) or targeted (LMNA and SCN5A) DCM genetic testing for patients with DCM and significant cardiac conduction disease (i.e. first, second or third degree heart block) and/or family history of premature unexplained death. In addition, they state that genetic testing can be useful for patients with familial DCM to confirm diagnosis, to recognize those who are at highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family and to help with family planning. Known familial mutation testing is recommended when a mutation has been identified in the family.
Although genetic testing is useful in differentiating between familial versus isolated DCM, and therefore facilitates identification of at-risk family members, management for the individual affected with DCM typically does not change once a diagnosis of familial DCM is established. The one exception to this is when a LMNA mutation is identified. In individuals identified with a LMNA mutation requiring pacemaker placement (i.e. history of arrhythmia or known risk of arrhythmia), the use of a pacing ICD rather than a pacemaker has been recommended due to the risk of ventricular arrhythmias and sudden death (Meune 2006).

In families where a mutation is not yet identified, clinical screening (physical exam, echocardiogram, and ECG) for DCM is recommended for asymptomatic at-risk relatives yearly in childhood and every 1-3 years in adults (Journal of Cardiac Failure Vol. 15 No. 2 2009). If there is family history of early onset disease or family history of sudden death, increased frequency of screening may be more appropriate.

Once a familial mutation is identified, genetic testing for the known familial mutation in asymptomatic family members can differentiate between relatives who are at high risk of DCM and sudden death, versus relatives who did not inherit the familial mutation and for whom clinical screening is not warranted.

**Hypertrophic Cardiomyopathy**

Hypertrophic cardiomyopathy (HCM) is characterized by increased size of the left ventricle of the heart, typically caused by thickening of the walls of the heart. The symptoms of HCM can be variable, ranging from no symptoms to shortness of breath or irregular heart rhythms, or sudden death. The irregular heart rhythms can occur without warning and may be life threatening. HCM has a prevalence of 1/500 individuals, making it one of the most common cardiac genetic diseases. It is inherited as an autosomal dominant trait with reduced penetrance. Family history focused on history of sudden death and age of onset in family members can be helpful in risk stratification.

HCM is the most common cause of sudden death in athletes, accounting for 30% of cases of young sudden death during competition. Approximately 5%-10% of individuals with HCM progress to end-stage disease with impaired systolic function and, in some cases, left ventricular dilatation and regression of LVH. The annual mortality rate in individuals with end-stage disease is estimated at 11% and cardiac transplantation may be required. Current testing is estimated (depending on number of genes tested - from 10 to 31 genes) to detect a mutation in 60-80% of individuals with HCM. Most of the mutations are found in sarcomeric proteins that are involved with contraction of the heart muscle, but undiagnosed glycogen storage disease can also present as HCM, as can transthyretin amyloidosis; some panels include these genes. Approximately 5% of patients will have two or more mutations identified (compound heterozygote); these patients often have an earlier age of onset and worse prognosis.

HCM is typically diagnosed clinically with cardiac imaging, physical exam, electrocardiogram, or based on histopathologic features at autopsy. Among persons with clinically diagnosed HCM, genetic testing is of unclear benefit for risk stratification, specifically sudden cardiac death (SCD) (Gersh et al., AHHF/AHA Guidelines, 2011). The major benefit of genetic testing in non-syndromic HCM lies in at-risk family member identification, prenatal testing, preimplantation genetic diagnosis, and, occasionally, distinguishing hereditary HCM from a secondary cause (e.g. uncontrolled hypertension, athlete’s heart).

In the absence of an identifiable pathogenic mutation in the family, medical management for individuals with a family history of HCM includes increased cardiac screening with physical examination, 12-lead EKG, annual two-dimensional echocardiography during adolescence, and in some cases cardiac MRI, with screening continuing every 5 years in adulthood. Given the possibility for late-onset disease,
screening well into adulthood is recommended. Once a mutation has been identified, testing negative for
a known familial mutation allows at-risk family members to discontinue all screening (which can be both
costly and time-consuming) (Gersh et al., AHHF/AHA Guidelines, 2011).

**Brugada Syndrome**

The diagnosis of Brugada Syndrome (BrS) is based on symptoms, electrocardiogram (EKG) and family
history. A diagnosis can be made based on EKG results and clinical history in approximately 75% of
persons. Genetic testing can also be helpful to make a diagnosis of BrS.

BrS is characterized by a specific pattern of EKG (ST segment elevation in leads V1-V3). This can be
associated with right bundle branch block, a defect in the heart’s conduction system that can also be
seen on EKG. This pattern may be seen on resting EKG or may require an EKG while receiving a drug
known as a sodium channel blocker. Symptoms of BrS can include arrhythmia or irregular heartbeats
and fainting spells. These symptoms often occur at rest. Other triggers include high fever, large meals
and excessive alcohol consumption. These BrS symptoms may be fatal if untreated.

Brugada syndrome typically presents in males in their 30s or 40s and is the second cause of death in
men from Southeast Asia under the age of 40 years. Implantable cardioverter defibrillators (ICDs) are the
only therapy currently known to be effective in persons with BrS with syncope or cardiac arrest.

Avoidance of certain medications is recommended for persons with Brugada syndrome, as well as
particular attention during a febrile state as this can be a risk factor for syncope.

At least sixteen genes are associated with Brugada syndrome. However, a recent study did not find a
significant association between mutations in genes other than SCN5A and arrhythmia in a European
population and warns about interpretation of variants in such other genes (Le Scouarnec 2015).

Mutations in the SCN5A gene are the most common genetic cause for Brugada syndrome (20-30%) and
account for >75% of BrS genotype positive persons. Targeted testing of SCN5A can be useful among
persons with clinical suspicion for BrS, according to HRS guidelines (2011). Genetic testing is not
indicated among persons with an isolated type 2 or 3 Brugada pattern on EKG. In most cases, the
primary value of genetic testing for Brugada syndrome is to benefit at-risk family members.

**Short QT Syndrome**

Short QT syndrome (SQTS) is a congenital, inherited, primary electric disorder of the heart characterized
by abnormally short QT intervals on the surface ECG (<360 ms) and an increased proclivity to develop
atrial and/or ventricular tachyarrhythmias (Gussak 2005). SQTS is a genetically heterogeneous disease
caused by mutations in five different genes (KCNH2, KCNQ1, KCNJ2, CACNA1C, and CACNB2B). All
follow autosomal dominant inheritance; KCNH2 mutations are by far the most common cause in affected
individuals (Patel 2010). However, mutation frequency and penetrance of these genes are uncertain.

HRS/EHRA guidelines regarding channelopathies and cardiomyopathies state that comprehensive or
targeted SQTS genetic testing may be considered for any patient in whom a cardiologist has established
a strong clinical index of suspicion for SQTS based on examination of the patient’s clinical history, family
history, and electrocardiographic phenotype (Class IIb-May be Useful) (HRS/EHRA 2011).

**Atrial Fibrillation**

Atrial fibrillation is characterized by uncoordinated electrical activity in the atria. Symptoms include
dizziness, chest pain, palpitations, shortness of breath, syncope and an increased risk of stroke and
sudden death. Some individuals with atrial fibrillation do not experience any symptoms. While the
majority of cases of AF are not hereditary, familial clustering does occur. Familial cases of AF are indistinguishable from acquired cases. Although a number of genes have been associated with an increased risk of AF, the role of these common genetic variants in risk stratification, assessment of disease progression, and determination of clinical outcomes is limited. Routine genetic testing related to AF is not indicated (January; ACC/AHA/HRS Practice Guidelines 2014).

**Post-Mortem Testing**

When plans cover genetic testing for the benefit of family members, postmortem genetic testing to confirm a diagnosis and allow for early detection of other family members should be considered. Best practice guidelines describe appropriate testing scenarios that include young (<40) unexplained sudden death and cases of suspected cardiomyopathies. Recent evidence suggests that genetic testing can help identify inherited cardiac disease in 25-35% of cases of sudden cardiac deaths.

Examples of suspicious circumstances at the time of death include: drowning in an experienced swimmer, single motor vehicle accident when no other factors present (negative toxicology screen), unexplained seizure in young person and sudden death during exercise or sleep.

**Professional Society Guidelines**

Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011 Aug;8(8):1308-39.


Lehnart SE, Ackerman MJ, Benson DW Jr, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping,


Selected References

Revision History

Clinical Steering Committee Review:

v3.2017 09/20/2017: Approved
v2.2017 03/29/2017: Approved
v1.2017 01/25/2017: Approved

Revisions:

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Editor</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>v3.2017</td>
<td>09/15/2017</td>
<td>Megan Czarniecki, MS, CGC</td>
<td>Revised general criteria language. Formatted references to NLM style. Moved methodological considerations to appropriate use criteria and background. Updated associated CPT codes, Renumbered to v3.2017 and submitted to CSC for approval.</td>
</tr>
<tr>
<td>v2.2017</td>
<td>06/19/2017</td>
<td>Kate Charyk, MS, CGC</td>
<td>Quarterly review. No criteria changes. Updated references.</td>
</tr>
<tr>
<td>v2.2017</td>
<td>04/21/2017</td>
<td>Kate Charyk, MS, CGC</td>
<td>Quarterly review. No criteria changes. Updated references.</td>
</tr>
<tr>
<td>v2.2017</td>
<td>03/29/2017</td>
<td>Kate Charyk, MS, CGC</td>
<td>Added criteria for post-mortem genetic testing. Updated references.</td>
</tr>
<tr>
<td>v1.2016</td>
<td>09/27/2016</td>
<td>Gwen Fraley, MS, CGC</td>
<td>Added general criteria. Updated references.</td>
</tr>
<tr>
<td>v1.2015</td>
<td>06/18/2015</td>
<td>Tricia See, MS, CGC</td>
<td>Original version</td>
</tr>
</tbody>
</table>

Original Effective Date: 06/18/2015
Primary Author: Tricia See, MS, CGC